152 related articles for article (PubMed ID: 16431306)
1. Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis.
Hawkey CJ; Gitton X; Hoexter G; Richard D; Weinstein WM
Clin Gastroenterol Hepatol; 2006 Jan; 4(1):57-66. PubMed ID: 16431306
[TBL] [Abstract][Full Text] [Related]
2. Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis.
Kivitz AJ; Nayiager S; Schimansky T; Gimona A; Thurston HJ; Hawkey C
Aliment Pharmacol Ther; 2004 Jun; 19(11):1189-98. PubMed ID: 15153172
[TBL] [Abstract][Full Text] [Related]
3. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
Matchaba P; Gitton X; Krammer G; Ehrsam E; Sloan VS; Olson M; Mellein B; Hoexter G; Orloff J; Garaud JJ
Clin Ther; 2005 Aug; 27(8):1196-214. PubMed ID: 16199245
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor.
Bannwarth B; Berenbaum F
Expert Opin Investig Drugs; 2005 Apr; 14(4):521-33. PubMed ID: 15882125
[TBL] [Abstract][Full Text] [Related]
6. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.
Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Matchaba P; Gimona A; Hawkey CJ;
Lancet; 2004 Aug 21-27; 364(9435):665-74. PubMed ID: 15325831
[TBL] [Abstract][Full Text] [Related]
7. Clinical trial: comparison of the gastrointestinal safety of lumiracoxib with traditional nonselective nonsteroidal anti-inflammatory drugs early after the initiation of treatment--findings from the Therapeutic Arthritis Research and Gastrointestinal Event Trial.
Hawkey CJ; Weinstein WM; Stricker K; Murphy V; Richard D; Krammer G; Rebuli R
Aliment Pharmacol Ther; 2008 May; 27(9):838-45. PubMed ID: 18221410
[TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
[TBL] [Abstract][Full Text] [Related]
9. Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study.
Hawkey CJ; Weinstein WM; Smalley W; Gitton X; Sallstig P; Stricker K; Krammer G; Mellein B; Richard D; Matchaba P
Gastroenterology; 2007 Jul; 133(1):57-64. PubMed ID: 17631131
[TBL] [Abstract][Full Text] [Related]
10. Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis.
Hawkey CC; Svoboda P; Fiedorowicz-Fabrycy IF; Nasonov EL; Pikhlak EG; Cousin M; Gitton X; Hoexter G
J Rheumatol; 2004 Sep; 31(9):1804-10. PubMed ID: 15338504
[TBL] [Abstract][Full Text] [Related]
11. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
[TBL] [Abstract][Full Text] [Related]
12. Lumiracoxib.
Lyseng-Williamson KA; Curran MP
Drugs; 2004; 64(19):2237-46; discussion 2247-8. PubMed ID: 15456339
[TBL] [Abstract][Full Text] [Related]
13. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.
Farkouh ME; Kirshner H; Harrington RA; Ruland S; Verheugt FW; Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Gimona A; Matchaba P; Hawkey CJ; Chesebro JH;
Lancet; 2004 Aug 21-27; 364(9435):675-84. PubMed ID: 15325832
[TBL] [Abstract][Full Text] [Related]
14. First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215].
Wittenberg RH; Schell E; Krehan G; Maeumbaed R; Runge H; Schlüter P; Fashola TO; Thurston HJ; Burger KJ; Trechsel U
Arthritis Res Ther; 2006; 8(2):R35. PubMed ID: 16469112
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics.
Hawkey CJ; Farkouh M; Gitton X; Ehrsam E; Huels J; Richardson P
Aliment Pharmacol Ther; 2004 Jul; 20(1):51-63. PubMed ID: 15225171
[TBL] [Abstract][Full Text] [Related]
16. A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients.
Stricker K; Yu S; Krammer G
BMC Musculoskelet Disord; 2008 Sep; 9():118. PubMed ID: 18778469
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo.
Sheldon E; Beaulieu A; Paster Z; Dutta D; Yu S; Sloan VS
Clin Ther; 2005 Jan; 27(1):64-77. PubMed ID: 15763607
[TBL] [Abstract][Full Text] [Related]
18. Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen: a pilot endoscopic study in healthy male subjects.
Rordorf C; Kellett N; Mair S; Ford M; Milosavljev S; Branson J; Scott G
Aliment Pharmacol Ther; 2003 Sep; 18(5):533-41. PubMed ID: 12950426
[TBL] [Abstract][Full Text] [Related]
19. Lumiracoxib in the treatment of osteoarthritis, rheumatoid arthritis and acute postoperative dental pain: results of three dose-response studies.
Schnitzer TJ; Gitton X; Jayawardene S; Sloan VS
Curr Med Res Opin; 2005 Jan; 21(1):151-61. PubMed ID: 15881487
[TBL] [Abstract][Full Text] [Related]
20. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
Bombardier C; Laine L; Reicin A; Shapiro D; Burgos-Vargas R; Davis B; Day R; Ferraz MB; Hawkey CJ; Hochberg MC; Kvien TK; Schnitzer TJ;
N Engl J Med; 2000 Nov; 343(21):1520-8, 2 p following 1528. PubMed ID: 11087881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
